

This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/advances

1	Starch nanoparticles prepared in two ionic liquids based
2	microemulsion system and their drug loading and release properties
3	Xinge Wang ¹ , Jianhua Cheng ² , Guangyin Ji ¹ , Xichun Peng ³ , Zhigang Luo ¹ *
4	1.Carbohydrate Lab, College of Food Science, South China University of
5	Technology, Guangzhou, 510640, China; 2. Ministry of Education Key Laboratory of
6	Pollution Control and Ecological Remediation for Industrial Agglomeration Area,
7	College of Environment and Energy, South China University of Technology,
8	Guangzhou 510006, China; 3. Department of Food Science and Engineering, College
9	of Science and Engineering, Jinan University, Guangzhou 510632, China
10	*Corresponding author:
11	Zhigang Luo, Tel: +86-20-87113845, Fax: +86-20-87113848. E-mail address:

12 <u>zhgluo@scut.edu.cn;</u>

1

RSC Advances Accepted Manuscript

13 ABSTRACT

In this work, 1-hexadecyl-3-methylimidazolium bromide ($[C_{16}mim]Br$) and 14 1-octyl-3-methylimidazolium acetate ($[C_8mim]Ac$) were simultaneously used as 15 substitutes for surfactants 16 and polar phase to prepare $[C_{16}mim]$ Br/butan-1-ol/cyclohexane/ $[C_8mim]$ Ac ionic liquid microemulsions. Then, 17 18 the structure of microemulsion was investigated by pseudo-ternary phase diagram, 19 dynamic light scanning (DLS) and conductivity measurement. Starch nanoparticles 20 with a mean diameter of 80.5 nm were prepared with Octenyl Succinic Anhydride 21 (OSA) starch as raw material through ionic liquid-in-oil (IL/O) microemulsion cross-linking reaction. Scanning electron microscope (SEM) data revealed that starch 22 nanoparticles were spherical granules with small size. In addition, the particles 23 presented homogeneous distribution and no aggregation phenomenon appeared. The 24 25 results of Fourier transform infrared spectroscopy (FTIR) identified the formation of cross-linking bonds in starch molecules. Finally, the drug loading and releasing 26 27 properties of starch nanoparticles were investigated with mitoxantrone hydrochloride as drug model. This work might provide an efficient method to synthesis starch 28 29 nanoparticles.

30 Keywords: [C₁₆mim]Br; [C₈mim]Ac; Ionic liquid microemulsion; Starch
31 nanoparticles; Drug loading; Drug releasing.

2

Starch, a renewable, biodegradable natural polymer with low-cost, has been widely 33 applied to food and industrial fields as thickener, gelling agent, bulking agent and 34 water retention agent.¹⁻³ However, native starch has limitations such as poor 35 processability and solubility, which limit its industrial application. Therefore, starch 36 can be modified using physical, chemical or enzymatic treatments to improve its 37 properties,⁴⁻⁶ among which cross-linked starch microspheres show good performance 38 39 towards swelling, high temperature, high shear and acidic conditions and have been one of the most investigated drug carriers due to their total biodegradability, 40 biocompatibility, high degree of swelling as well as simple fabrication process.^{7,8} So 41 they are promising vehicles in drug delivery systems especially in the intranasal drug 42 delivery system.9 43

44 Starch microspheres have been synthesized through several approaches,¹⁰⁻¹³ among 45 which water-in-oil (W/O) emulsion-cross-linking technique is widely used. However, 46 cross-linked starch microspheres prepared by traditional W/O emulsion-cross-linking 47 technique show relatively large size and broad size distribution,^{14, 15} which limit the 48 application in drug delivery systems. Therefore, a new method is desperately expected 49 to develop for the synthesis of starch nanoparticles.

50 Due to the specific chemical and physical properties, such as low melting point, 51 negligible vapor pressure and non-flammability and recyclability, room-temperature 52 ionic liquids (ILs) have been widely used.^{16,17} Studies related with ionic liquid 53 microemulsions in which ILs substitute polar phase, nonpolar phase or surfactant have

54 been reported, and some inorganic nanomaterials can be prepared in this kind of system.¹⁸⁻²¹ Additional, some ILs containing Cl⁻, Ac⁻, NO₃⁻ anions have been reported 55 to be capable of dissolving starch.²²⁻²⁴ For example, it has been reported 56 1-octyl-3-methylimidazolium acetate ([C₈mim]Ac) can dissolve starch, and also 57 substitute polar phase of microemulsions, So $[C_8 mim]Ac$ containing starch may 58 substitute polar phase to form ionic liquid microemulsions. As an important series of 59 60 ionic liquids 1-alkyl-3-methylimidazolium salts, [C_nmim]X have amphiphilicity like traditional cationic surfactant because of their hydrophobic chains and polar 61 imidazolium groups, and have been called "surfactant-like" ionic liquids.²⁵ In 62 microemulsion systems, Long-chained [C_nmim]X can be used as substitute for 63 surfactants to stabilize microemulsions. 64

In this research, 1-hexadecyl-3-methylimidazolium bromide ($[C_{16}mim]Br$) and 65 [C₈mim]Ac were simultaneously used as substitutes for surfactants and polar phase to 66 prepare $[C_{16}mim]Br/butan-1-ol/cyclohexane/[C_8mim]Ac$ ionic liquid microemulsions. 67 68 Then, the structure of microemulsions was studied by pseudo-ternary phase diagram, dynamic light scanning (DLS) and conductivity measurement. To decrease the 69 aggregation of nanoparticles, Octenyl Succinic Anhydride (OSA) starch was used as 70 71 raw material because of it's hydrophobicity. Starch nanoparticles were prepared with 72 IL/O microemulsion system and characterized by scanning electron microscopy (SEM), dynamic light scattering (DLS), Fourier transform infrared spectroscopy 73 74 (FTIR). Moreover, the drug loading and releasing properties of starch nanoparticles were studied with mitoxantrone hydrochloride as drug model. There is no report about 75

76	the preparation of starch nanoparticles in two ionic liquids based microemulsion
77	system, so this work may provide an efficient and environment method to synthesis
78	starch nanoparticles and broaden the application of starch nanoparticles in medical
79	filed.

80

81 **2. Material and methods**

82 2.1 Materials

1-hexadecyl-3-methylimidazolium bromide ($[C_{16}mimBr]$, >99%) and 1-octyl-3-methylimidazolium acetate ($[C_8mim]Ac$, >99%) were purchased from Lanzhou Institute of Chemical Physics (Lanzhou, China). Native corn starch was obtained from ChangChun DaCheng Corn Products Co. (Changchun, China). All other chemicals were of analytical grade.

88

89 **2.2 Preparation of ionic liquid microemulsion**

The preparation of $[C_{16}mim]Br/butan-1-ol/cyclohexane/[C_8mim]Ac microemulsion$ 90 system was conducted by direct visual observation. An appropriate amount of 91 surfactant (0.1937g), $[C_8 mim]$ Ac (0.1800g, the mass ratio of $[C_8 mim]$ Ac to surfactant 92 93 ω =0.93), and cyclohexane (1mL) was taken into test tubes, and their masses were 94 determined by an FA1104N analytical balance (Shanghai Balance Instrument Co., Shanghai, China) with a resolution of 0.0001g. Then, the tubes were placed in the 95 thermostatic water bath. The cosurfactant butan-1-ol was slowly added in small 96 intervals to the mixture with constant stirring until the hierarchical and hazy solution 97

RSC Advances Accepted Manuscript

98 became clear, which was indicative of the formation of the single phase.

99

100 **2.3 Pseudo-ternary phase diagram**

Fixed amounts of $[C_{16}mim]Br$, $[C_8mim]Ac/water and different amounts of oil were$ taken into test tubes and kept in a thermostatic water bath at 40 °C. The cosurfactantbutan-1-ol was slowly added to the mixture until the solution became just clear. Theclear point indicated the formation of single-phase system. The same procedure wasrepeated for 3 times for each mixture, and an average of these results was taken forthe pseudo-ternary phase diagram.

107

108 **2.4 Dynamic light scanning**

Dynamic light scanning was used to determine the size distribution of $[C_{16}mim]Br/butan-1-ol/cyclohexane/[C_8mim]Ac$ microemulsions and further demonstrate the formation of microemulsions. Measurements were conducted using the Malvern Nano-Zetasizer particle size analyzer (Malvern Instrument Ltd., Worcestershire, UK) at a wavelength of 633 nm. The scattering angle was set at 90°.

114

115 2.5 Conductivity measurements

116 $[C_{16}mim]Br$ and butan-1-ol were mixed as surfactant by the mass ratio of 3:1. 117 $[C_8mim]Ac (0.5 \text{ g})$ was added to the mixture of surfactant and cyclohexane each time, 118 and then conductivity values were measured until the solution became turbid. The 119 conductivity of microemulsion was measured using a model DDSJ-308A

6

120	conductometer (Shanghai Precision Scientific Instrument Co., Shanghai, China) at 1
121	kHz using a dip-type cell of cell constant 0.971 cm^{-1} . Conductometer had been
122	corrected by distilled water, and the errors in the conductance measurements were
123	±0.5%.
124	
125	2.6 Preparation of OSA modified native corn starch
126	Native corn starch (10 g, dry weight) was suspended in distilled water (35%, w/w)
127	with agitation, and then placed in a water bath at 35 °C. The pH of the slurry was
128	adjusted to 8.5 with 3% (w/w) NaOH solution. 3% (based on starch dry weight) OSA
129	was added slowly over 2h, and pH was controlled at 8.5 by a pH controller (Model
130	501-3400, Barnant Co.). The reaction was allowed to continue for a further 1 h, and
131	then pH was adjusted to 6.5 with 3% HCl solution. The mixture was centrifuged,
132	washed two times with distilled water and two times with 70% aqueous alcohol. The
133	sample was oven-dried at 40 $^{\circ}$ C for 24 h, and passed through a 180 mesh nylon sieve
134	(90 µm opening).

135

136 **2.7 Determination of degree of substitution (DS)**

The degree of substitution (DS) is the average number of hydroxyl groups substituted per glucose unit. The DS of OSA starch was determined by titration. Briefly, 1.5 g of OSA starch was accurately weighed and dispersed in 50 mL of 95% ethanol by stirring for 10 min. Then 15 mL of 2 mol/L HCl alcohol solution was added and the slurry was stirred for a further 30 min. The suspension was filtered

142	through a glass filter and the residue was washed with 90% alcohol solution until no							
143	Cl^{-} could be detected (using 0.1 mol/L AgNO ₃ solution). The starch was redispersed							
144	in 100 mL of distilled water and cooked in a boiling water bath for 20 min, then							
145	titrated with 0.1 mol/L standard NaOH solution using phenolphthalein as an indicator.							
146	A blank was simultaneously titrated with native corn starch as a sample.							
147	The DS was calculated as follow:							
148	DS = 0.1624A/(1-0.21A) (1)							
149	Where A (mmol) is the amount of standard sodium hydroxide solution (0.1 mol/L)							
150	consumed by each gram OSA starch.							
151	According to the calculation, the DS of the modified starch was 0.0172.							
152								
153	2.8 Preparation and Characterization of starch nanoparticles							
154	2.8.1 Preparation of starch nanoparticles							
155	Starch nanoparticles were prepared according to IL/O microemulsion-cross-linking							
156	method with OSA starch as raw material, epichlorohydrin as cross-linker. This method							
157	combined the ionic liquid microemulsion with cross-linking reaction of starch							
158	nanoparticles. First, the water phase was prepared by dissolving OSA starch (0.5 g)							
159	into $[C_8mim]$ Ac (9.5g), stirred for homogeneous mixing and heated in an oil bath at							
160	135 °C for 2.5 h. Then [C_8mim]Ac-starch solution and cyclohexane (40g) were							
161	added into the small beaker to form IL/O microemulsion with the aid of 20g of the							
162	mixture of surfactant $[C_{16}mim]Br$ and cosurfactant butan-1-ol							
163	([C ₁₆ mim]Br/butan-1-ol=3:1, w/w). After the ionic liquid microemulsions containing							
	8							

164	OSA starch were formed, epichlorohydrin (1.4 g) was added to the above
165	microemulsion as cross-linker. Then, the mixture was stirred at 50 $^\circ\!\mathrm{C}$ for 3 h. The
166	reaction solution was cooled to room temperature and starch nanoparticles were
167	subsequently precipitated with anhydrous ethanol under vigorous stirring followed by
168	centrifugation. The precipitate was washed thoroughly with sufficient anhydrous
169	ethanol to eliminate $[C_{16}mim]Br$, unreacted epichlorohydrin, butan-1-ol and
170	cyclohexane. Finally, the solid was centrifuged and dried in vacuum at 40 $^\circ\!\!\mathbb{C}$ for 24
171	h.

172

173 **2.8.2** Characterization of starch nanoparticles

SEM images of samples were examined by scanning electron microscope (Quanta 200, FEI, Oregon, USA). The accelerating voltage was 20 kV. The samples were mounted on an aluminum stub with double sticky tape, followed coating with the gold in a vacuum before examination.

The particle size and distribution of starch nanoparticles were determined by DLS (Nano ZS, Malvern Instrument Ltd., Worcestershire, UK). Before measuring, 0.01 g of starch nanoparticles were added to 100 mL distilled water and treated by ultrasound for 1h to disperse sufficiently.

The FTIR spectra of samples were recorded on a Nicolet 510 spectrophotometer (Thermo Electron, Waltham, USA) using KBr disk technique. For FTIR measurement, the samples were mixed with anhydrous KBr and then compressed into thin disk-shaped pellets. The spectra were obtained with a resolution of 2 cm⁻¹ between a 186 wave number range of $400-4000 \text{ cm}^{-1}$.

187

188 **2.9 Drug loading and release properties of starch nanoparticles**

189 **2.9.1 Standard curves of mitoxantrone hydrochloride**

190 Standard curves of mitoxantrone hydrochloride in phosphate-buffered saline (PBS, 191 0.2 mol/L, pH 7.4) were obtained as follow: 0.01 mg/mL of mitoxantrone 192 hydrochloride in PBS solution was scanned at the wavelength between 400~800nm 193 with ultraviolet–visible spectrophotometer (TU-1901, Beijing Puxi General Apparatus, 194 Ltd., China). The wavelength at which mitoxantrone hydrochloride absorbed the most was selected as the testing wavelength for later experiments. Then, 0.01, 0.02, 0.04, 195 196 0.08, 0.10 and 0.12 mg/mL of mitoxantrone hydrochloride in PBS solution were 197 measured at their corresponding testing wavelengths to obtain standard curves of 198 mitoxantrone hydrochloride absorbance to concentration for each solution.

199

200 **2.9.2 Drug loading analysis**

About 0.1 g of starch nanoparticles were weighed and suspended in 20 mL of PBS solution with 0.02 0.04, 0.08, and 0.12 mg/mL of mitoxantrone hydrochloride each. The resulting suspensions were gently stirred at the desired temperature of 17, 27, 37, and 47 °C for 0.5, 1, 1.5, 2 and 2.5 h, respectively. Then, the solutions were centrifuged, and 1 mL of each supernatant was extracted and diluted to certain volume to determine the drug loading amount and encapsulation efficiency according to the standard curve of mitoxantrone hydrochloride absorbance. The drug loading amount

208 (A) and encapsulation efficiency (B) were calculated with the following equations,209 respectively.

210
$$A = (C_0 - C_1 V_1) V_0 / W$$
(2)

211
$$B = (C_0 - C_1 V_1) / C_0$$
(3)

Where C_0 means initial concentration of mitoxantrone hydrochloride in PBS solution, C_1 means diluted concentration of mitoxantrone hydrochloride in PBS solution, V_1 means dilution volume of extracted supernatant, V_0 means initial volume of PBS solution, and W means the weight of starch nanoparticles dissolved in PBS solution.

217

218 **2.9.3 Drug release analysis**

219 About 0.1 g of drug-loaded starch nanoparticles that possessed the most drug 220 loading (4.97 mg/g) under the experimental conditions above were weighed and 221 added to the dialysis tube. Then, 10 mL of phosphate buffer solution (PBS, pH=7.4) 222 was added to the dialysis tube. Subsequently, the drug-loaded starch nanoparticles and 223 dialysis tube were placed in a beaker containing 90 mL of PBS and slowly stirred in magnetic stirring apparatus at 37 °C. 5 mL of PBS solution with starch nanoparticles 224 225 was taken out and the sample drawn was replaced by fresh PBS to maintain a constant 226 volume. The cumulative release rate was determined according to the standard curve 227 of mitoxantrone hydrochloride absorbance to concentration and Eq (4).

228
$$R = M_1 / M_0$$
 (4)

229 Where M₁ is the cumulative mass of mitoxantrone hydrochloride released from

230	drug-loaded starch nanoparticles at a given time, and M_0 is the total drug loading						
231	amount in starch nanoparticles.						
232							
233	2.9.4 Statistical analysis						
234	All of the sample analyses were conducted in triplicate and the values were						
235	expressed as means ± standard error of the mean, Statistical analysis were done using						
236	SPSS 18.0. Duncan's multiple range tests were used to estimate significant differences						
237	among means at a probability level of 0.05.						
238							
239	3 Results and discussion						
240	3.1 Pseudo-ternary phase diagram						
241	The pseudo-ternary phase diagram of the [C ₁₆ mim]Br/butan-1-ol						
242	/cyclohexane/[C ₈ mim]Ac (water) microemulsion system with fixed ω value (ω =0.93)						
243	at 40° C is shown in Fig. 1. Apparently, two different regions, a single-phase region						
244	(1Φ) and a two-phase region (2Φ) , could be observed. The single phase region						
245	contained IL/O (W/O) microemlusion. In addition, when $[C_8mim]Ac$ replaced water						
246	phase to form microemulsion, the single phase region grew, which indicated that						
247	[C ₈ mim]Ac as water phase was more beneficial to the formation of the single phase						
248	microemulsion compared with water.						
249							
250	3.2 Dynamic light scanning						
251	The size distribution of the droplets in the IL/O microemulsion was characterized						

by DLS. A series of $[C_{16}mim]Br/butan-1-ol/cyclohexane/[C_8mim]Ac microemulsions$ $with different R values (the mass ratio of <math>[C_8mim]Ac$ to cyclohexane) were chosen for DLS analysis. As shown in **Fig. 2**, the sizes of microemulsions increased from about 3.1 to 13.4 nm with increasing R values from 1:9 to 4:6. The microemulsions showed regular swelling behavior with the increase of $[C_8mim]Ac$, which indicated the formation of IL/O microemulsion according to the studies by Pramanik *et al.* and Gao *et al.*.^{26, 27}

259

3.3 Conductivity measurements

In this work, IL/O microemulsions system was chosen as the cross-linking 261 262 reaction system for the preparation of starch nanoparticles. The conductivity 263 measurements were widely used to determine the structure of microemulsions. 264 According to the percolation conductance model, with the increase of $[C_8 \text{mim}]Ac$, 265 conductivity curve can be divided into three segments: the sharp rise, flat and the drop 266 of last, corresponding to three ultrastructural structures of microemulsions droplets IL/O, BC (Bicontinuous Cubic) and O/IL, respectively.²⁸ As shown in Fig. 3, for the 267 mass ratio of surfactant to cyclohexane 2:8, 3:7 and 4:6, the conductivities of 268 269 microemulsions all rose sharply with the increase of $[C_8mim]Ac$. Therefore, only 270 IL/O microemulsions formed when the mass ratio of surfactant to cyclohexane was between 2:8 and 4:6. 271

272

273 **3.4 SEM analysis**

The morphologies of OSA starch and starch nanoparticles were observed by SEM. As shown in **Fig. 4**, OSA starch granules were polygonal or irregular shapes and the surface was rough. Compared with OSA starch, starch nanoparticles were spherical granules and much smaller than OSA starch. In addition, compared with starch nanoparticles prepared by Liu *et al.* and Zhou *et al.*,^{29, 30} the particles presented more homogeneous distribution and no aggregation phenomenon appeared.

3.5 Particle size and distribution of starch nanoparticles

DLS was used to measure the particle size and distribution of starch nanoparticles. As we can see from **Fig. 5**, starch nanoparticles had a relatively concentrated size distribution and the mean diameter was 80.5 nm, which was much smaller than that of starch microspheres prepared by the traditional W/O emulsion cross-linking method.³¹ The result of DLS was also consistent with the data in **Fig. 4**. So IL/O microemulsion-cross-linking method is an ideal way to produce starch nanoparticles with a relatively concentrated distribution and smaller size.

289

290 **3.6 FTIR analysis**

The FTIR spectra of OSA starch and starch nanoparticles are shown in **Fig. 6**. For the FTIR spectrum of OSA starch, the extremely broad band at 3400 cm⁻¹ and the peak at 2926 cm⁻¹ corresponded to O-H and C-H stretching, respectively. Two characteristic peaks at 1727, and 1570 cm⁻¹ were attributed to C=O and C=C stretching vibrations of OSA starch, respectively. Meanwhile, the band at 1645 cm⁻¹

296	was assigned to O–H bending vibration. Besides, other bonds at 1156, 1081, and 1018
297	cm ⁻¹ were attributed to the C–O bond stretching vibrations of anhydroglucose units.
298	Compared with OSA starch, the spectra of starch nanoparticles exhibited some
299	difference. The absorption peak at 3456 cm ⁻¹ became lankier and shifted slightly to
300	high frequency regions, ³² which was due to the weakening of the hydrogen band
301	connection in cross-linking reaction. In addition, the peak at 1727 cm ⁻¹ disappeared,
302	the peaks at 1654 and 1581cm ⁻¹ became much weaker, and the peaks at 1174, 1094
303	and 1032cm ⁻¹ changed and band intensity got stronger. All these results suggested that
304	cross-linking bonds were formed between starch molecules. Similar result was also
305	reported by Mundargi when they studied the FTIR of starch microspheres ⁸ .

306

307 3.7 Drug loading analysis

According to the scanning results, the testing wavelengths of mitoxantrone hydrochloride were 610 nm. Moreover, standard curve of mitoxantrone hydrochloride absorbance to concentration (from 0.01 to 0.12 mg/mL) in PBS solution was A=25.43C+0.013, $R^2=0.999$.

The effect of loading time on drug loading amount and encapsulation efficiency is shown in **Table 1**. As shown in **Table 1**, with the lengthening of loading time, the drug loading amount and enhanced encapsulation efficiency of mitoxantrone hydrochloride increased first and then decreased between 0.5 and 2.5 h (P<0.05). To be more exact, the drug loading amount increased from 0.52 to 0.98 mg/g and encapsulation efficiency rose from 6.52 to 12.43% when the loading time extended

from 0.5 to 1.5 h. However, with the time extending from 2.0 to 2.5 h, the drug loading amount and encapsulation efficiency decreased to 0.46 mg/g and 5.75%, respectively. Therefore, it can be concluded that the optimal loading time was 1.5 h. As shown in Table 2 , loading temperature affected drug loading amount and encapsulation efficiency of mitoxantrone hydrochloride to some extent (P <0.05). The drug loading amount encapsulation efficiency ascended with the rise of loading temperature from 17 to 27°C and reached the maximum at 27°C. The reason was that the sorption of mitoxantrone hydrochloride was mainly attributed to the existence of opposite charges and high affinity, ³⁰ which would be blocked by high temperature. So with the loading temperature reaching 47 °C, the drug loading amount and encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively. The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3 , which revealed that the rise in mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (P <0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property.		
loading amount and encapsulation efficiency decreased to 0.46 mg/g and 5.75%, respectively. Therefore, it can be concluded that the optimal loading time was 1.5 h. As shown in Table 2 , loading temperature affected drug loading amount and encapsulation efficiency of mitoxantrone hydrochloride to some extent ($P<0.05$). The drug loading amount encapsulation efficiency ascended with the rise of loading temperature from 17 to 27°C and reached the maximum at 27°C. The reason was that the sorption of mitoxantrone hydrochloride was mainly attributed to the existence of opposite charges and high affinity, ³⁰ which would be blocked by high temperature. So with the loading temperature reaching 47 °C, the drug loading amount and encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively. The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3 , which revealed that the rise in mitoxantrone hydrochloride concentration efficiency increased first and then significantly ($P<0.05$). However, encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitated drug loading property.	318	from 0.5 to 1.5 h. However, with the time extending from 2.0 to 2.5 h, the drug
respectively. Therefore, it can be concluded that the optimal loading time was 1.5 h. As shown in Table 2 , loading temperature affected drug loading amount and encapsulation efficiency of mitoxantrone hydrochloride to some extent (P <0.05). The drug loading amount encapsulation efficiency ascended with the rise of loading temperature from 17 to 27°C and reached the maximum at 27°C. The reason was that the sorption of mitoxantrone hydrochloride was mainly attributed to the existence of opposite charges and high affinity, ³⁰ which would be blocked by high temperature. So with the loading temperature reaching 47 °C, the drug loading amount and encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively. The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3 , which revealed that the rise in mitoxantrone hydrochloride concentration efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property.	319	loading amount and encapsulation efficiency decreased to 0.46 mg/g and 5.75%,
As shown in Table 2 , loading temperature affected drug loading amount and encapsulation efficiency of mitoxantrone hydrochloride to some extent (P <0.05). The drug loading amount encapsulation efficiency ascended with the rise of loading temperature from 17 to 27°C and reached the maximum at 27°C. The reason was that the sorption of mitoxantrone hydrochloride was mainly attributed to the existence of opposite charges and high affinity, ³⁰ which would be blocked by high temperature. So with the loading temperature reaching 47 °C, the drug loading amount and encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively. The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3 , which revealed that the rise in mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (P <0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property.	320	respectively. Therefore, it can be concluded that the optimal loading time was 1.5 h.
encapsulation efficiency of mitoxantrone hydrochloride to some extent (P <0.05). The drug loading amount encapsulation efficiency ascended with the rise of loading temperature from 17 to 27°C and reached the maximum at 27°C. The reason was that the sorption of mitoxantrone hydrochloride was mainly attributed to the existence of opposite charges and high affinity, ³⁰ which would be blocked by high temperature. So with the loading temperature reaching 47 °C, the drug loading amount and encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively. The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3 , which revealed that the rise in mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (P <0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property.	321	As shown in Table 2, loading temperature affected drug loading amount and
drug loading amount encapsulation efficiency ascended with the rise of loading temperature from 17 to 27°C and reached the maximum at 27°C. The reason was that the sorption of mitoxantrone hydrochloride was mainly attributed to the existence of opposite charges and high affinity, ³⁰ which would be blocked by high temperature. So with the loading temperature reaching 47 °C, the drug loading amount and encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively. The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3 , which revealed that the rise in mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (P <0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property.	322	encapsulation efficiency of mitoxantrone hydrochloride to some extent (P <0.05). The
temperature from 17 to 27°C and reached the maximum at 27°C. The reason was that the sorption of mitoxantrone hydrochloride was mainly attributed to the existence of opposite charges and high affinity, ³⁰ which would be blocked by high temperature. So with the loading temperature reaching 47 °C, the drug loading amount and encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively. The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3 , which revealed that the rise in mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (<i>P</i> <0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property.	323	drug loading amount encapsulation efficiency ascended with the rise of loading
the sorption of mitoxantrone hydrochloride was mainly attributed to the existence of opposite charges and high affinity, ³⁰ which would be blocked by high temperature. So with the loading temperature reaching 47 °C, the drug loading amount and encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively. The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3 , which revealed that the rise in mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (P <0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property.	324	temperature from 17 to 27°C and reached the maximum at 27°C. The reason was that
326opposite charges and high affinity, 30 which would be blocked by high temperature. So327with the loading temperature reaching 47 °C, the drug loading amount and328encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively.329The effect of mitoxantrone hydrochloride concentration on the drug loading amount330and encapsulation efficiency is depicted in Table 3, which revealed that the rise in331mitoxantrone hydrochloride concentration facilitated drug loading amount332significantly ($P < 0.05$). However, encapsulation efficiency increased first and then333decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to3340.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the335concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher336mitoxantrone hydrochloride concentration did not facilitate drug loading property.	325	the sorption of mitoxantrone hydrochloride was mainly attributed to the existence of
with the loading temperature reaching 47 °C, the drug loading amount and encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively. The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3 , which revealed that the rise in mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (P <0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property.	326	opposite charges and high affinity, ³⁰ which would be blocked by high temperature. So
 encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively. The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3, which revealed that the rise in mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (<i>P</i><0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property. 	327	with the loading temperature reaching 47 °C, the drug loading amount and
The effect of mitoxantrone hydrochloride concentration on the drug loading amount and encapsulation efficiency is depicted in Table 3 , which revealed that the rise in mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (<i>P</i> <0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property.	328	encapsulation efficiency reduced to only 2.73 mg/g and 16.84%, respectively.
 and encapsulation efficiency is depicted in Table 3, which revealed that the rise in mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (<i>P</i><0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property. 	329	The effect of mitoxantrone hydrochloride concentration on the drug loading amount
 mitoxantrone hydrochloride concentration facilitated drug loading amount significantly (P<0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property. 	330	and encapsulation efficiency is depicted in Table 3, which revealed that the rise in
 significantly (P<0.05). However, encapsulation efficiency increased first and then decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property. 	331	mitoxantrone hydrochloride concentration facilitated drug loading amount
 decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property. 	332	significantly ($P < 0.05$). However, encapsulation efficiency increased first and then
 0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property. 	333	decreased with the concentration of mitoxantrone hydrochloride rising from 0.02 to
 concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher mitoxantrone hydrochloride concentration did not facilitate drug loading property. 	334	0.12 mg/mL and the maximum encapsulation efficiency attained 21.22% when the
mitoxantrone hydrochloride concentration did not facilitate drug loading property.	335	concentration of mitoxantrone hydrochloride reached 0.08 mg/mL. Therefore, higher
	336	mitoxantrone hydrochloride concentration did not facilitate drug loading property.

337

338 **3.8 Drug release analysis**

339 The mitoxantrone hydrochloride release property of starch nanoparticles is

340 presented in Fig. 7. Initially, a significant release could be clearly observed after the 341 drug-loaded starch nanoparticles were immersed into PBS solution. High release rate 342 of 54.36% in the first 1 h was assigned to the immediate dispersing of mitoxantrone hydrochloride close to the starch microspheres surfaces. In the next 9 h, the 343 drug-loaded starch nanoparticles formed a swelling-controlled and sustained release 344 system, in which the release rate showed a slight but slow rise. 91.47% of MB 345 346 contained in the starch nanoparticles was released in the 10th hour, and the release of 347 mitoxantrone hydrochloride reached a balance between starch microspheres and PBS 348 solution, only tiny amount of mitoxantrone hydrochloride was released due to the sluggish degradation of starch particles. These observed results were consistent with 349 that of Fang et al.¹⁵ when they studied the release property of starch microsphere. 350

351

352 4 Conclusions

This work described an exploratory research on the preparation of starch 353 354 nanoparticles based on a novel ionic liquid microemulsion system and the drug 355 loading releasing of and properties starch nanoparticles. $[C_{16}mim]$ Br/butan-1-ol/cyclohexane/ $[C_8mim]$ Ac ionic liquid microemulsions was 356 357 prepared. Then, the structure of microemulsions was identified by pseudo-ternary 358 phase diagram, DLS and conductivity measurement. Starch nanoparticles were prepared with IL/O microemulsion system as reaction system and OSA starch as raw 359 360 material. SEM results revealed that starch nanoparticles were spherical granules with 361 small size, in addition, the particles presented more homogeneous distribution and no

RSC Advances Accepted Manuscript

aggregation phenomenon appeared. DLS date showed the mean diameter of starch nanoparticles was 80.5 nm. The formation of cross-linking bonds between starch molecules was identified by FTIR. In terms of drug loading property of starch nanoparticles, it was found that the drug loading and encapsulation efficiency were influenced by loading time, loading temperature, and drug concentration to some extent (P<0.05). The release curve of drug-loaded starch nanoparticles contained two phases: an initial burst release phase and a sustained release phase.

369

370 Acknowledgements

This research was supported by the National Natural Science Foundation of China 371 372 (21376097, 21576098, 21004023), the program for New Century Excellent Talents in 373 University (NCET-13-0212), the Guangdong Natural Science Foundation 374 (S2013010012318), the Key Project of Science and Technology of Guangdong Province (2015A020209015, 2014A020208016, 2013B090500013), the Key Project 375 of Science and Technology of Guangzhou City (201508020082,2014J4500012), the 376 377 National Natural Science Fund of China (Foundation of Guangdong Province of 378 China; U1401235), the Fundamental Research Funds for the Central Universities, 379 SCUT (2015ZZ0070, 2014ZZ0052).

380

381 **References**

1 L.M. Che, D. Li, L.J. Wang, N. Özkan, X.D. Chen and Z.H. Mao, Int. J. Food Prop.,

383 2007, **10**, 911-922.

- 2 R.F. Tester, J. Karkalas and X. Qi, J. Cereal Sci., 2004, **39**, 151–165.
- 385 3 Z.G. Luo and Z.Y. Xu, *LWT-Food Sci. Technol.*, 2011, 44, 1993–1998.
- 4 S. Jobling, *Current Opin Plant Biol.*, 2004, 7, 210–218.
- 5 C.S. Raina, S. Singh, A.S. Bawa and D.C.A. Saxena, Food Sci. Technol., 2007, 40,
- **388 885–892**.
- 389 6 X.X. Lu, Z.G. Luo, S.J. Yu and X. Fu, J. Agric. Food Chem., 2012, 60, 9273-9279.
- 390 7 M. Kim and S.J. Lee, *Carbohydr. Polym.*, 2002, **50**, 331–337.
- 391 8 R.C. Mundargi, N.B. Shelke, A.P. Rokhade, S.A. Patil and T.M. Aminabhavi,
- 392 *Carbohydr. Polym.*, 2008, **71**, 42–53.
- 393 9 S.R. Mao, Z.M. Chen, Z.P. Wei, H. Liu and D.Z. Bi, *Int. J. Pharm.*, 2004, 272,
 394 37–43.
- 10 J.M. Bezemer, R. Radersma, D.W. Grijpma, P.J. Dijkstra, C.A. Van Blitterswijk
 and J. Feijen, *J. Contro. Release.*, 2000, 67, 233–248.
- 397 11 M. Kawashitaa, M. Tanakab, T. Kokuboc, Y. Inoued, T. Yaoe and S. Hamadaf,
- *Biomaterials*, 2005, **26**, 2231–2238.
- 399 12 M. Luck, K.F. Pistel, Y.X. Li, T. Blunk, R.H. Muller and T. Kissel, J. Contro.
- 400 *Release.*, 1998, **55**, 107–120.
- 401 13 C. Sturesson and J. Carlfors, J. Contro. Release., 2000, 67, 171–178.
- 402 14 O. Franssen and W.E. Hennink, Int. J. Pharm., 1998, 168, 1–7.
- 403 15 Y.Y. Fang, L.J. Wang, D. Li, B.Z. Li, B. Bhandari, X.D. Chen and Z.H. Mao,
- 404 *Carbohydr. Polym.*, 2008, **74**, 379–384.
- 405 16 R. Sheldon, *Chem. Rev.*, 2001, 23, 2399–2407.

- 406 17 T. Welton, *Chem. Rev.*, 1999, **99**, 2071–2083.
- 407 18 S.Q. Cheng, X.G. Fu, J.H. Liu, J.L. Zhang, Z.F. Zhang and Y.L. Wei, Colloids Surf.
- 408 *A*, 2007, **302**, 211–215.
- 409 19 S.Q. Cheng, F. Han, Y.R. Wang and J.F. Yan, *Colloids Surf. A*, 2008, **317**, 457–461.
- 410 20 H.X. Gao, J.C. Li, B.X. Han, W.N. Chen, J.L. Zhang, R. Zhang and Y.D. Yan, *Phys.*
- 411 *Chem. Chem. Phys.*, 2004, **6**, 2914–2916.
- 412 21 F. Yan and J. Texter, *Chem. Commun.*, 2006, **25**, 2696–2698.
- 413 22 Q. Liu, M.H.A. Janssen, F. Van Rantwijk and R. Sheldon, Green Chem., 2005, 7,
- 414 39–42.
- 415 23 A.A. Rosatella, L.C. Branco and C.A.M. Afonso, *Green Chem.*, 2009, 11,
 416 1406–1413.
- 417 24 R.L. Shogren and A. Biswas, *Carbohydr. Polym.*, 2010, **81**, 149–151.
- 418 25 S. Thomaier and W. Kunz, J. Mol. Liq., 2007, **130**, 104-107.
- 419 26 R. Pramanik, C. Ghatak, V.G. Rao, S. Sarkar and N.J. Sarkar, J. Phys. Chem. B,
- 420 2011, **115**, 5971–5979.
- 421 27 Y. Gao, S. Han, B. Han, G. Li, D. Shen, Z. Li, J. Du, W. Hou and G. Zhang,
- 422 *Langmuir*, 2005, **21**, 5681–5684.
- 423 28 M. Lagues, M. Dvolaitzky, J.P. Le Pesant and R. Ober, *J. Phys. Chem.*, 1980, 84,
 424 1532-1535.
- 425 29 J. Liu, F.H. Wang, L.L. Wang, S.Y. Xiao, C.Y. Tong, D.Y. Tang and X.M. Liu, J.
- 426 *Cent. South Univ. Technol.*, 2008, **15**, 768-773.
- 427 30 G. Zhou, Z.G. Luo, X. Fu, J. Agric. Food Chem., 2014, **62**, 8214-8220.

428	31	X.F.	Zhao,	Z.J.	Li,	L.	Wang	and	X.J.	Lai,	J.	Appl.	Polym.	Sci.,	2008,	109,
429		2571	-2575.													

430 32 Y.T. Yang, X.Z. Wei, P. Sun and J.M. Wan, *Molecules*, 2010, **15**, 2872-2875.

Loading time (h)	Drug loading amount (mg/g)	Encapsulation efficiency (%)
0.5	0.52±0.025 ^{C,D}	6.52 ± 0.055^{D}
1	$0.70 \pm 0.040^{\mathrm{B}}$	8.75 ± 0.060^{B}
1.5	$0.98{\pm}0.045^{\rm A}$	12.43±0.075 ^A
2	$0.58{\pm}0.045^{\circ}$	7.45±0.055 ^C
2.5	$0.46{\pm}0.030^{ m D}$	5.75±0.040 ^E

431	Table 1	Effect of lo	bading time	on mitoxantrone	hydrochloride	loading.
			4 /			4 /

Values represent the means \pm SD; n = 3. Values in a column followed by different capital letters as superscripts were significantly different from each other according to Duncan's multiple range tests (p < 0.05).

	Loading temperature (°C)	Drug loading amount (mg/g)	Encapsulation efficiency (%)
_	17	$3.44{\pm}0.045^{B}$	21.32±0.345 ^B
	27	3.75±0.055 ^A	23.17±0.281 ^A
	37	3.26±0.065 ^C	$20.15 \pm 0.400^{\circ}$
	47	2.73±0.035 ^D	16.84±0.211 ^D

435	Table 2 Effect of loading	temperature on mitoxantrone	hydrochloride loading.
	Ŭ	1	

Values represent the means \pm SD; n = 3. Values in a column followed by different capital letters as superscripts were significantly different from each other according to Duncan's multiple range tests (p < 0.05).

Drug concentration (mg/mL)	Drug loading amount (mg/g)	Encapsulation efficiency (%)
0.02	0.46 ± 0.050^{D}	11.53±0.242 ^C
0.04	0.92±0.041 ^C	12.59±0.285 ^B
0.08	3.36±0.074 ^B	21.22±0.215 ^A
0.12	4.97±0.045 ^A	20.96±0.180 ^A

439 Table 3 Effect of mitoxantrone	hydrochloride c	concentration of	n drug loading.
---	-----------------	------------------	-----------------

Values represent the means \pm SD; n = 3. Values in a column followed by different capital letters as superscripts were significantly different from each other according to Duncan's multiple range tests (p < 0.05).

443	Figure captions		
444	Fig.1 Pseudo-ternary phase diagrams of [C ₁₆ mim]Br/butan-1-ol/cyclohexane/water (A)		
445	and [C ₁₆ mim]Br/butan-1-ol/cyclohexane/[C ₈ mim]Ac (B) microemulsion systems.		
446			
447	Fig.2 Size distribution of $[C_{16}mim]Br/butan-1-ol/cyclohexane/[C_8mim]Ac$		
448	microemulsions. ω represents the mass ratio of [C ₈ mim]Ac to cyclohexane.		
449			
450	Fig.3 The conductivity of microemulsion system with the different mass ratio of		
451	surfactant and cyclohexane.		
452			
453	Fig.4 SEM of OSA starch \times 1000 (A) and starch particles \times 40000 (B).		
454			
455	Fig.5 The particle size and distribution of starch nanoparticles.		
456			
457	Fig.6 FTIR of OSA starch (a) and starch nanoparticles (b).		
458			
459	Fig.7 Mitoxantrone hydrochloride release of starch nanoparticles in PBS solution		
460			



Fig. 1 Pseudo-ternary phase diagrams of [C₁₆mim]Br/butan-1-ol/cyclohexane/water

463 (A) and $[C_{16}mim]Br/butan-1-ol/cyclohexane/[C_8mim]Ac (B) microemulsion systems.$



465 **Fig. 2** Size distribution of [C₁₆mim]Br/butan-1-ol/cyclohexane/[C₈mim]Ac







469

467

surfactant to cyclohexane.

RSC Advances Accepted Manuscript





471 **Fig. 4** SEM of OSA starch×1000 (A) and starch nanoparticles×40000 (B).





Fig. 5 The particle size and distribution of starch nanoparticles.





476

Fig. 7 Mitoxantrone hydrochloride release of starch nanoparticles in PBS solution.



Graphical abstract

1